Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 17/20 | 0.56 |
| ▸ | EGLN3 | Q9H6Z9 | 6/20 | 0.56 |
| ▸ | VEGFA | P15692 | 2/20 | 0.54 |
| ▸ | FLT1 | P17948 | 2/20 | 0.54 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.53 |
| ▸ | HIF1AN | Q9NWT6 | 2/20 | 0.53 |
| ▸ | TET3 | O43151 | 1/20 | 0.53 |
| ▸ | ASPH | Q12797 | 1/20 | 0.53 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.53 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.53 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.53 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.53 |
| ▸ | FTO | Q9C0B1 | 7/20 | 0.48 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.48 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.48 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.46 |
| ▸ | KDM6B | O15054 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31028951 | 1.00 | EGLN1 (0.56) | EGLN1EGLN3VEGFAFLT1BBOX1 | |
| SCHEMBL968220 | 0.89 | EGLN1 (0.56) | EGLN1EGLN3VEGFAFLT1BBOX1 | |
| SCHEMBL821712 | 0.82 | KDM4C (0.58) | EGLN1EGLN3BBOX1HIF1ANFTO | |
| SCHEMBL7738848 | 0.79 | PIM1 (0.46) | — | |
| SCHEMBL8629264 | 0.78 | EGLN1 (0.51) | EGLN1EGLN3VEGFAFLT1BBOX1 | |
| SCHEMBL1508856 | 0.78 | KMT2A (0.47) | EGLN1EGLN3VEGFAFLT1BBOX1 | |
| SCHEMBL30274514 | 0.77 | EGLN1 (0.53) | EGLN1EGLN3VEGFAFLT1BBOX1 | |
| SCHEMBL2540006 | 0.77 | EGLN1 (0.53) | EGLN1EGLN3VEGFAFLT1BBOX1 | |
| SCHEMBL6567256 | 0.77 | EGLN1 (0.50) | EGLN1EGLN3VEGFAFLT1FTO | |
| SCHEMBL8625460 | 0.77 | EGLN1 (0.55) | EGLN1EGLN3VEGFAFLT1BBOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021259471-A1 | DERMAL FILLER WITH HIF-1α ACTIVITY MODULATORS | THOR DOMINIK (AT) | 2021-12-30 | — | — | WO | claimed |
| CN-101664408-B | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN INC | 2013-05-01 | — | — | CN | claimed |
| EP-1658074-B1 | INHIBITORS OF 2-OXOGLUTARATE DIOXYGENASE AS GAMMA GLOBIN INDUCERS | FIBROGEN INC (US) | 2012-11-07 | — | — | EP | claimed |
| US-8202834-B2 | Fat regulation | FIBROGEN, INC. (US) | 2012-06-19 | — | — | US | claimed |
| US-8124582-B2 | stabilizing alpha subunit of hypoxia inducible factor protein (HIF alpha ), thereby regulating glucose metabolism; preventing or treating hyperglycemia, obesity, hypertension, hyperlipidemia, nephropathy, neuropathy, retinopathy, impaired glucose tolerance, atherosclerosis, and vascular disease | FIBROGEN, INC. (US) | 2012-02-28 | — | — | US | claimed |
| EP-1919463-B9 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2011-02-02 | — | — | EP | claimed |
| US-20100168152-A1 | Fat regulation | FIBROGEN, INC. (US) | 2010-07-01 | — | — | US | claimed |
| EP-1919463-B1 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2010-06-09 | — | — | EP | claimed |
| US-7618940-B2 | Fat regulation | FIBROGEN, INC. (US) | 2009-11-17 | — | — | US | claimed |
| WO-2007146425-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA | FIBROGEN, INC. (US) | 2007-12-21 | — | — | WO | claimed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| US-11969417-B2 | Topical formulation for use in alopecia | TOMORROWLABS GMBH (AT) | 2024-04-30 | — | — | US | disclosed |
| EP-3917525-B1 | NEW TOPICAL FORMULATION FOR USE IN ALOPECIA | TOMORROWLABS GMBH (AT) | 2024-02-28 | — | — | EP | disclosed |
| US-11680047-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680048-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| WO-2003049686-A2 | STABILIZATION OF HYPOXIA INDUCIBLE FACTOR (HIF) ALPHA | FIBROGEN, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| US-5726305-A | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-03-10 | — | — | US | disclosed |
| US-5719164-A | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-02-17 | — | — | US | disclosed |
| EP-0765871-A1 | Substituted Quinoline-2-carboxamides, their preparation and their use as prolyle-4-hydroxylase Inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | EGLN1 863/4885EGLN3 557/4885VEGFA 2447/4885 |
| US-11680048-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | EGLN1 24/4885EGLN3 7/4885VEGFA 211/4885 |
| US-11680047-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | EGLN1 21/4885EGLN3 6/4885VEGFA 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.